INTERNATIONAL PATENT: SERMONIX PHARMACEUTICALS, INC. FILES APPLICATION FOR "LASOFOXIFENE TREATMENT OF ER+ CANCERS WITH CONSTITUTIVELY ACTIVE ESR1 MUTATIONS"

GENEVA, Aug. 12 -- SERMONIX PHARMACEUTICALS, INC. (250 East Broad Street, Suite 250Columbus, OH 43215) filed a patent application (PCT/US2025/013606) for "LASOFOXIFENE TREATMENT OF ER+ CANCERS WITH CONSTITUTIVELY ACTIVE ESR1 MUTATIONS" on Jan 29, 2025. With publication no. WO/2025/165887, the details related to the patent application was published on Aug 07, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): PORTMAN, David J. (c/o Sermonix Pharmaceuticals, Inc.250 East Broad Street, Suite 250Columbus, OH 43215), KOMM, Barry Samuel (c/o Sermonix Pharmaceuticals, Inc.250 East Broad Street, Suite ...